



## KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary

Vicente E Torres, Curie Ahn, Thijs R M Barten, Godela Brosnahan, Melissa A Cadnapaphornchai, Arlene B Chapman, Emilie Cornec-Le Gall, Joost P H Drenth, Ron T Gansevoort, Peter C Harris, et al.

### ► To cite this version:

Vicente E Torres, Curie Ahn, Thijs R M Barten, Godela Brosnahan, Melissa A Cadnapaphornchai, et al.. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. *Kidney International*, 2025, 107 (2), pp.234-254. 10.1016/j.kint.2024.07.010 . hal-05036891

**HAL Id: hal-05036891**

**<https://hal.science/hal-05036891v1>**

Submitted on 16 Apr 2025

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC-ND 4.0 - Attribution - Non-commercial use - No Derivative Works - International License

# KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary



OPEN

Vicente E. Torres<sup>1</sup>, Curie Ahn<sup>2</sup>, Thijs R.M. Barten<sup>3</sup>, Godela Brosnahan<sup>4</sup>, Melissa A. Cadnapaphornchai<sup>5,6</sup>, Arlene B. Chapman<sup>7</sup>, Emilie Cornec-Le Gall<sup>8,9</sup>, Joost P.H. Drenth<sup>3</sup>, Ron T. Gansevoort<sup>10</sup>, Peter C. Harris<sup>1</sup>, Tess Harris<sup>11,†</sup>, Shigeo Horie<sup>12</sup>, Max C. Liebaw<sup>13,14,15,16</sup>, Michele Liew<sup>17</sup>, Andrew J. Mallett<sup>18</sup>, Changlin Mei<sup>19</sup>, Djalila Mekahli<sup>20,21</sup>, Dwight Odland<sup>22</sup>, Albert C.M. Ong<sup>23</sup>, Luiz F. Onuchic<sup>24</sup>, York P-C. Pei<sup>25</sup>, Ronald D. Perrone<sup>26</sup>, Gopala K. Rangan<sup>27</sup>, Brian Rayner<sup>28</sup>, Roser Torra<sup>29</sup>, Ethan M. Balk<sup>30</sup>, Craig E. Gordon<sup>26,30</sup>, Amy Earley<sup>31</sup>, Reem A. Mustafa<sup>32</sup> and Olivier Devuyst<sup>33,34</sup>

<sup>1</sup>Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; <sup>2</sup>Laboratory of Transplantation Immunology, Seoul National University, Seoul, South Korea; <sup>3</sup>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; <sup>4</sup>Department of Medicine, University of Colorado, Aurora, Colorado, USA; <sup>5</sup>Division of Nephrology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; <sup>6</sup>Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; <sup>7</sup>Section of Nephrology, University of Chicago, Chicago, Illinois, USA; <sup>8</sup>Department of Nephrology, Centre de reference MALadies Rénales Héritaires de l'Enfant et de l'Adulte (MARHEA), University Hospital of Brest, Brest, France; <sup>9</sup>Division of Nephrology, Inserm UMR1078, Brest, France; <sup>10</sup>Department of Nephrology, University of Groningen, Groningen, The Netherlands; <sup>11</sup>Polycystic Kidney Disease Charity UK, London, UK; <sup>12</sup>Department of Urology, Juntendo University, Tokyo, Japan; <sup>13</sup>Department of Pediatrics, Center for Rare Diseases, Medical Faculty, Cologne, Germany; <sup>14</sup>Department of Pediatrics, Center for Family Health, Medical Faculty, Cologne, Germany; <sup>15</sup>Department of Pediatrics, Center for Molecular Medicine, Medical Faculty, Cologne, Germany; <sup>16</sup>University Hospital Cologne, Cologne, Germany; <sup>17</sup>Patient partner, Hong Kong, China; <sup>18</sup>Department of Renal Medicine, Townsville University Hospital, Townsville, Queensland, Australia; <sup>19</sup>Department of Nephrology, Changzheng Hospital, Shanghai, China; <sup>20</sup>Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium; <sup>21</sup>Department of Pediatric Nephrology, University Hospital Leuven, Leuven, Belgium; <sup>22</sup>PKD Foundation, Los Angeles, California, USA; <sup>23</sup>Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; <sup>24</sup>Division of Nephrology, Universidade de São Paulo, São Paulo, Brazil; <sup>25</sup>Division of Nephrology, University of Toronto, Toronto, Ontario, Canada; <sup>26</sup>Division of Nephrology, Tufts University School of Medicine, Boston, Massachusetts, USA; <sup>27</sup>Department of Renal Medicine, Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia; <sup>28</sup>Division of Nephrology and Hypertension, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa; <sup>29</sup>Department of Nephrology, Fundació Puigvert, IR Sant Pau, Barcelona, Spain; <sup>30</sup>Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island, USA; <sup>31</sup>KDIGO, Brussels, Belgium; <sup>32</sup>Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas, Kansas City, Kansas, USA; <sup>33</sup>Institute of Physiology, University of Zurich, Zurich, Switzerland; and <sup>34</sup>Division of Nephrology, Cliniques universitaires Saint-Luc, UCLouvain Medical School, Brussels, Belgium

**The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) represents the first KDIGO guideline on this subject. Its scope includes nomenclature, diagnosis, prognosis, and prevalence; kidney manifestations; chronic kidney disease**

**(CKD) management and progression, kidney failure, and kidney replacement therapy; therapies to delay progression of kidney disease; polycystic liver disease; intracranial aneurysms and other extrarenal manifestations; lifestyle and psychosocial aspects; pregnancy and reproductive issues; pediatric issues; and approaches to the management of people with ADPKD. The guideline has been developed with patient partners, clinicians, and researchers around the world, with the goal to generate a useful resource for healthcare providers and patients by providing actionable recommendations. The development of this guideline followed an explicit process of evidence review and appraisal, based on a rigorous, formal systematic literature review. The strength of recommendations follows the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The guideline also provides practice points serving to direct clinical care or activities relating to areas for which a systematic review was not**

**Correspondence:** Vicente E. Torres, Mayo Clinic 200 First Street SW, Rochester, Minnesota 55905, USA. E-mail: [torres.vicente@mayo.edu](mailto:torres.vicente@mayo.edu) or Olivier Devuyst, Cliniques universitaires Saint-Luc, UCLouvain Medical School, 10 Avenue Hippocrate, B-1200 Brussels, Belgium. E-mail: [olivier.devuyst@saintluc.uclouvain.be](mailto:olivier.devuyst@saintluc.uclouvain.be) or [olivier.devuyst@uzh.ch](mailto:olivier.devuyst@uzh.ch)

The complete KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) is published in *Kidney International*, volume 107, issue 2S, 2025, which is available online at [www.kidney-international.org](http://www.kidney-international.org).

<sup>†</sup>Deceased.

Received 14 June 2024; revised 28 June 2024; accepted 10 July 2024

conducted. Limitations of the evidence are discussed. Research recommendations to address gaps in knowledge, and implications for policy and payment, are provided. The guideline targets a broad audience of healthcare providers, people living with ADPKD, and stakeholders involved in the various aspects of ADPKD care.

*Kidney International* (2025) **107**, 234–254; <https://doi.org/10.1016/j.kint.2024.07.010>

KEYWORDS: ADPKD; evidence-based; guideline; monogenic disease; nomenclature

Copyright © 2024, Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. on behalf of the International Society of Nephrology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**A**utosomal dominant polycystic kidney disease (ADPKD) is a major genetic disorder affecting millions of people worldwide, and the fourth most common global cause for kidney replacement therapy. The Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on ADPKD was held in Edinburgh in 2014.<sup>1</sup> Since then, the genetic and clinical landscapes of ADPKD have evolved; distinct imaging patterns and prognostic tools have been identified; results of randomized controlled trials (RCTs) of tolvaptan, somatostatin analogues, levels of blood pressure (BP) targets, renin–angiotensin blockade, and other potential treatments for ADPKD have been published; and tolvaptan has been approved for the treatment of rapidly progressive ADPKD. With the sustained increase in knowledge, and the expansion of the volume of information, a global KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD has become timely.


The *KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD* has been developed by an international, multidisciplinary Work Group with expertise in ADPKD, a dedicated Evidence Review Team, and the KDIGO staff. The guideline includes 10 chapters addressing the whole scope of ADPKD diagnosis and management. The focus is on clinical management questions based on high-certainty scientific evidence collected by the Evidence Review Team. The guideline includes graded recommendations, based on the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) criteria and supported by systematic reviews, and ungraded practice points, based on expert opinion or limited evidence serving to direct clinical activities, for which a systematic review was not conducted. Both recommendations and practice points are intended to help guide clinical practice and to aid in decision-making. The KDIGO 2025 ADPKD Guideline has considered disparities in available resources, as well as possible cultural differences in different parts of the world.

This report summarizes the main recommendations and practice points of the guideline (Supplementary Table S1). For more detailed information, the reader is referred to the full guideline, including grading details, a complete reference list, and a research agenda (Supplementary Table S2), available at <https://kdigo.org/guidelines/autosomal-dominant-polycystic-kidney-disease-adpkd/>.<sup>2</sup>

## Chapter 1: Nomenclature, prevalence, diagnosis, and prognosis

**Definition and nomenclature.** The term ADPKD comprises a group of dominantly inherited disorders associated with kidney cysts and extrarenal manifestations caused by a pathogenic variant in one gene associated with ADPKD. The usual phenotype of ADPKD includes multiple, bilateral kidney cysts causing progressive kidney enlargement, commonly associated with hypertension and liver cysts. Complications may include abdominal fullness and pain, cyst hemorrhage, gross hematuria, nephrolithiasis, cyst infections, and reduced quality of life. Kidney function decline typically occurs in adulthood, resulting in kidney failure (KF), usually after the fourth decade of life.<sup>3,4</sup>

The major ADPKD genes are *PKD1* and *PKD2*, accounting for >90% of diagnosed families. Several minor genes account for a small percentage of affected families. To address the genetic complexity of ADPKD, we suggest a naming format that uses a descriptor of the disease followed by the causal gene (Figure 1). In people with ADPKD and a pathogenic variant in either *PKD1*, *PKD2*, or a minor gene for which pathogenicity is well supported (*IFT140*, *ALG5*, *ALG9*, *GANAB*, *DNAJB11*, *NEK8*), the nomenclature should include ADPKD followed by the gene name (e.g., ADPKD-*PKD1*; Table 1). People who have an ADPKD-spectrum phenotype and have not been genetically tested or had genetic testing, with no pathogenic variant in an ADPKD gene identified, or who have a variant in a minor gene for which pathogenicity remains uncertain (*ALG6*, *ALG8*, *PKHD1*), should continue to be termed as having ADPKD. The designation of ADPKD should not be based on the finding of a likely pathogenic variant in a minor gene when a clinical diagnosis of ADPKD is uncertain. This nomenclature allows maintenance of the familiar disease name and may imply characteristics associated with the specific causal gene (e.g., many minor ADPKD genes confer a very low



**Figure 1 | Nomenclature of autosomal dominant polycystic kidney disease (ADPKD) dependent on phenotype, family history, availability and results of genetic testing.** PKD, polycystic kidney disease.

**Table 1 | ADPKD genes and proposed nomenclature**

| Disease designation   | Gene                                 | Screened families, % | Kidney phenotype   | Extrarenal phenotype                                      | Comments  |
|---|--------------------------------------|----------------------|--|---|---|
| <b>Major ADPKD genes and nomenclature for unknown, not screened, and unresolved typical cases</b> |                                      |                      |  |   |   |
| ADPKD   | Unknown, not screened, or unresolved | —                    | Bilateral PKD, kidney enlargement, age-related CKD, may result in KF in adulthood (Chapters 2–3)                                 | Typical presentation (Chapters 5–6)                       | Wide phenotypic range   |
| Truncating pathogenic variant: ADPKD- <i>PKD1</i>   | <i>PKD1</i>                          | ~48                  | Bilateral PKD, early kidney enlargement, CKD G3, age around 40 yr, KF in 50s (Chapters 2–3)                                      | Typical presentation (Chapters 5–6)                       | Often severe, but more benign course possible, sometimes associated with mosaicism  |
| Nontruncating pathogenic variant: ADPKD- <i>PKD1</i>  |                                      | ~19                  | Bilateral PKD, kidney enlargement, age-related CKD, may result in KF (Chapters 2–3)  | Typical presentation (Chapters 5–6)                       | Phenotype ranges from severe (similar to <i>PKD1</i> truncating) to mild, partly depending on the degree of residual protein function |
| ADPKD- <i>PKD2</i>  | <i>PKD2</i>                          | ~15                  | Bilateral PKD, milder and later kidney enlargement, CKD G3, age around 55 yr, KF in 70s (Chapters 2–3)                           | Typical presentation (Chapters 5–6)                       | Includes some disease variability including a more severe or more benign course   |
| <b>Minor ADPKD genes with definitive-to-moderate evidence of disease involvement</b>              |                                      |                      |  |   |   |
| ADPKD- <i>ALG5</i>  | <i>ALG5</i>                          | <0.5                 | Low-to-moderate cyst number, limited kidney enlargement and fibrosis; CKD and some KF in older subjects                          | A few liver cysts in a minority of people                 |   |
| ADPKD- <i>ALG9</i>  | <i>ALG9</i>                          | <0.5                 | Low-to-moderate cyst number, significant CKD in older adults   | Frequent liver cysts                                      | Biallelic mutations are associated with the congenital disorder of glycosylation, type IL (CDGIL)                                     |
| ADPKD- <i>DNAJB11</i>   | <i>DNAJB11</i>                       | <0.5                 | Bilateral small cysts, limited or no kidney enlargement, progressive fibrosis, limited CKD G3a age <55 yr, but KF at ages in 70s | Liver cysts, usually mild, possible ICA and vascular risk | Similarities to ADTKD, but visible cysts usually present; biallelic mutations associated with renal-hepatic-pancreatic dysplasia      |
| ADPKD- <i>GANAB</i>   | <i>GANAB</i>                         | <0.5                 | Mild PKD, limited CKD, no KF   | Liver cysts, sometimes severe PLD, ICA unclear            | Can present as ADPLD  |
| ADPKD- <i>IFT140</i>  | <i>IFT140</i>                        | 1–2                  | Few, large bilateral cysts, kidney enlargement, kidney function usually preserved into old age                                   | Liver cysts rarely, risk of ICA unclear                   | Biallelic mutations associated with short-rib thoracic dysplasia and retinitis pigmentosa   |
| ADPKD- <i>NEK8</i>  | <i>NEK8</i>                          | <0.5                 | Bilateral PKD, kidney enlargement, KF in childhood, occasionally later in cases of specific alleles or mosaicism                 | Liver cysts rarely  | <i>De novo</i> occurrence in 75%; biallelic mutations associated with renal-hepatic-pancreatic dysplasia and nephronophthisis         |

ADPKD, autosomal dominant polycystic kidney disease; ADPLD, autosomal dominant polycystic liver disease; ADTKD, autosomal dominant tubulointerstitial kidney disease; CKD, chronic kidney disease; ICA, intracranial aneurysm; KF, kidney failure; PKD, polycystic kidney disease; PLD, polycystic liver disease.

risk of KF), whereas *PKD1* and *PKD2* (and *DNAJB11*) are associated with a substantial risk of KF.


Polycystic liver disease (PLD) is the most frequent extra-renal manifestation of ADPKD. Autosomal dominant polycystic liver disease (ADPLD) is a different monoallelic disease causing PLD, but with no or few kidney cysts, linked to *PRKCSH* and *SEC63* and a few additional genes.<sup>5</sup> We suggest a naming format similar to that for ADPKD for autosomal dominant polycystic liver disease.

**Prevalence.** The estimated prevalence of ADPKD in population-based studies, and of pathogenic *PKD1* or *PKD2* mutations in the general population (1 per 1000), is higher than the point prevalence of diagnosed ADPKD in large databases (2–4 per 10,000). Cystic kidneys are the cause of KF in

~5% of people receiving kidney replacement therapy in Europe and North America, whereas very few prevalence studies have been performed in populations from Asia and Africa.


**Diagnosis.** Appropriate counseling about the possible benefits and risks should be provided to people at risk of ADPKD, before imaging or genetic screening is scheduled, and after screening, to help interpret the results and plan next steps. The values and preferences of the person should be central to these discussions.

We recommend abdominal imaging by ultrasound to screen adults at risk. Age-specific numbers of cysts have been described to diagnose or exclude ADPKD in people with a positive family history (Figure 2; Supplementary Figure S1).



**Figure 2 | Diagnosis algorithm in adults at risk (with a positive family history) for autosomal dominant polycystic kidney disease (ADPKD).** ACMG, American College of Medical Genetics and Genomics; MRI, magnetic resonance imaging. \*ADPKD diagnosis is confirmed by ultrasound if  $\geq 3$  total cysts are present (ages 15–39 years),  $\geq 2$  cysts are present in each kidney (ages 40–59 years), or  $\geq 4$  cysts are present in each kidney (age  $\geq 60$  years); the diagnosis is ruled out if  $\leq 1$  cyst is present (ages 15–39 years) or  $\leq 2$  cysts total are present (ages 40–59 years). ADPKD diagnosis is confirmed by MRI if  $>10$  cysts total are present, and it is ruled out if  $<5$  cysts total are present (ages 16–40 years). †Computed tomography, either with or without contrast, also can be used. Abdominal ultrasound is suggested as the first imaging analysis, with follow-up MRI analysis and/or genetic testing recommended in people with equivocal imaging or atypical extrarenal features or if additional prognostic information is requested. In genetically resolved families, simple testing of the family variant usually provides a diagnosis. Occasionally, if the disease presentation is very different from the family disease, broader genetic testing may be helpful. Solid lines indicate tests that are suggested, and dashed lines indicate tests to consider.





**Figure 3 | Diagnosis algorithm in adults with incidentally detected kidney and/or liver cysts in absence of known family history of autosomal dominant polycystic kidney disease (ADPKD).** Solid lines indicate tests that are suggested, and dashed lines indicate tests to consider. \*CT with or without contrast also can be used. ACMG, American College of Medical Genetics and Genomics; CT, computed tomography; GFR, glomerular filtration rate; MRI, magnetic resonance imaging; US, ultrasound.

For people with a positive family history of ADPKD aged 16–40 years, the cutoff of >10 cysts on magnetic resonance imaging (MRI) has been used to diagnose ADPKD, and the cutoff of <5 cysts has been used to exclude ADPKD. These ultrasound and MRI criteria apply to only families with pathogenic variants of *PKD1* or *PKD2*, and not to those with pathogenic variants to minor genes. In a family with a known pathogenic variant, targeted screening for the specific variant is usually sufficient to diagnose or exclude ADPKD. For people with detected kidney cysts, but no known family history of ADPKD, kidney imaging and genetic testing may help to make a diagnosis (Figure 3).

Genetic testing is particularly helpful in cases involving few kidney cysts; variable intrafamilial disease severity, including very-early-onset ADPKD; discordant imaging and glomerular filtration rate; negative family history; young (aged <30 years) living-related kidney donors at risk of ADPKD, based on family history; and family planning and preimplantation diagnosis.

Several inherited diseases may mimic ADPKD with kidney and/or liver cysts as part of their phenotype (Table 2).<sup>6–8</sup>

**Prognosis.** The causal gene (*PKD1* > *PKD2* or minor genes), type of *PKD1* mutation (truncating > nontruncating), sex (male > female), and environmental factors (obesity, salt intake) are associated with the severity of ADPKD.


We recommend employing the Mayo Imaging Classification (MIC) to predict future decline in kidney function and the timing of KF. The MIC is divided into typical (class 1) and atypical (class 2) ADPKD. Prognostic information is valid for only class 1 patients with typical imaging findings (Figure 4). The MIC uses height-adjusted total kidney volume, adjusted for age, to stratify people with typical imaging into 5 groups (1A–1E), indicating accelerating decline in kidney function. The height-adjusted total kidney volume is measured most accurately by MRI or computed tomography (CT) scan, using an automated or semiautomated tool, or alternatively, it can be estimated using the ellipsoid equation. Ultrasound-determined total kidney volume and kidney length are less precise but have prognostic value. The MIC should not be used in people with pathogenic variants in genes other than *PKD1* or *PKD2*. The Predicting Renal Outcome in PKD score, and estimated GFR (eGFR) in relation to age and/or

**Table 2 | Inherited disorders that present with kidney and/or liver cysts and may mimic ADPKD**

| Disorders and gene  | Disease   | Inheritance     |
|---|---|-----------------|
| <b>Developmental disorders</b>                                      |   |                 |
| <i>HNF1B</i>  | <i>HNF1B</i> -related kidney disease  | AD*             |
| <i>JAG1</i> , <i>NOTCH2</i>   | Alagille syndrome   | AD              |
| <b>Collagen disorders</b>   |   |                 |
| <i>COL4A1</i>   | HANAC syndrome  | AD              |
| <i>COL4A3</i> , <i>COL4A4</i> , <i>COL4A5</i>                       | COL4A-related diseases  | AD and X-linked |
| <b>Nephrolithiasis</b>  |   |                 |
| <i>CYP24A1</i> , <i>SLC34A3</i> , <i>HOGA1</i>                      | Kidney stones, nephrocalcinosis   | AR (AD)         |
| <b>Autosomal dominant tubulointerstitial kidney disease (ADTKD)</b> |   |                 |
| <i>UMOD</i> , <i>MUC1</i> , <i>REN</i> , <i>SEC61A</i>              | ADTKD   | AD              |
| <b>Autosomal dominant polycystic liver disease (ADPLD)</b>          |   |                 |
| <i>PRKCSH</i> , <i>SEC63</i> , <i>GANAB</i>                         | ADPLD   | AD              |
| <b>Autosomal recessive polycystic kidney disease (ARPKD)</b>        |   |                 |
| <i>PKHD1</i> , <i>DZIP1L</i> , <i>CYS1</i> , <i>PKD1</i>            | ARPKD   | AR              |
| <i>PMM2</i>   | HIPKD   | AR              |
| <b>Tumorous disorders</b>   |   |                 |
| <i>FLCN</i>   | Birt-Hogg-Dubé syndrome   | AD              |
| <i>TSC1</i> , <i>TSC2</i>   | Tuberous sclerosis complex  | AD              |
| <i>PKD1/TSC2</i>  | <i>PKD1/TSC2</i> -CGS   | AD              |
| <i>VHL</i>  | Von Hippel-Lindau syndrome  | AD              |
| <i>FH</i>   | HLRCC   | AD              |
| <b>Syndromic ciliopathies</b>                                       |   |                 |
| <i>OFD1</i>   | Oral-facial-digital syndrome 1  | X-linked        |
| <i>NPHP1</i> and other <i>NPHP</i> genes                            | Nephronophthisis  | AR              |
| Many genes  | Syndromic ciliopathies such as Joubert, Bardet Biedl, Meckel syndrome, and short rib thoracic dystrophy | AR              |
| <b>Acquired disorders</b>   |   |                 |
| None  | Simple cysts  | Sporadic        |
| None  | ACD   | Acquired        |

ACD, acquired cystic disease; AD, autosomal dominant; ADPKD, autosomal dominant polycystic kidney disease; AR, autosomal recessive; CGS, contiguous gene syndrome; COL, collagen; HANAC, hereditary angiopathy with nephropathy, aneurysms, and muscle cramps; HIPKD, hyperinsulinemic hypoglycemia and polycystic kidney disease; HLRCC, hereditary leiomyomatosis and renal cell cancer; NPHP, nephronophthisis.

\*Up to 50% of cases appear *de novo*.





longitudinal eGFR slope, can aid in the identification of people who have rapidly progressive ADPKD.<sup>4</sup>

## Chapter 2: Kidney manifestations

**High blood pressure (BP).** Management of high BP in people with ADPKD should include regular BP monitoring, dietary and lifestyle modifications (see Chapter 7), and pharmacotherapy when indicated.

As in all people with chronic kidney disease (CKD), we recommend standardized office BP measurement in people with ADPKD, regardless of kidney function.<sup>11</sup> We suggest that out-of-office BP measurements with home BP-monitoring or ambulatory BP-monitoring be used to complement standardized office BP readings. Use of ambulatory BP-monitoring should be considered with difficult-to-control BP or left ventricular hypertrophy, proteinuria, or declining kidney function but normal office BP readings.

We recommend using renin-angiotensin system inhibitors—that is, angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), as the first-line treatment to achieve the target BP. We recommend avoiding any combination of ACEi, ARB, and direct renin-inhibitor therapy. The appropriate choice of second-line antihypertensive agents will depend on assessing the benefits and risks for individual people.

Based on available RCT results, we recommend a target BP of  $\leq 110/75$  mm Hg, as measured by home BP-monitoring, if tolerated, for people aged 18–49 years with CKD G1–G2 and BP  $>130/85$  mm Hg. For those aged 18–49 years with CKD G1–G2 and BP  $<130/85$  mm Hg but  $>110/75$  mm Hg, we suggest using an individualized approach to BP control, incorporating shared decision-making between the healthcare provider(s) and the patient. For those aged  $\geq 50$  years and/or with CKD G3–G5, we recommend a target mean systolic blood pressure of  $<120$  mm Hg, if tolerated, assessed using standardized office BP measurement.

Resistant high BP requiring  $\geq 3$  drugs should be investigated for patient compliance or other causes of hypertension. High-grade proteinuria should be investigated for a coexisting kidney disease.

**Kidney pain.** Flank, abdominal, or lumbar pain in people with ADPKD should be investigated, to determine whether it is kidney-related or not. Refractory kidney pain is best managed by a multidisciplinary team, and pain-management strategies guided by shared decision-making. Nonpharmacologic, noninvasive interventions generally should be considered initially, followed by pharmacologic treatment if they do not relieve pain. Referral to a center of expertise should be made when invasive intervention is considered. Cyst aspiration or aspiration sclerotherapy may be considered when pain can be attributed to a single or several dominant cysts. Celiac plexus block, either in isolation or followed by major splanchnic nerve block, and percutaneous renal denervation, may be effective in the treatment of selected people with refractory chronic visceral

pain caused by cyst enlargement. Spinal-cord stimulation may provide significant pain relief in specific cases of moderate-to-severe refractory mechanical or visceral pain. Nephrectomy is reserved for severe intractable pain, typically with advanced kidney disease or after KF, in those who have failed to respond to other modalities.


**Nephrolithiasis.** Medical treatment of nephrolithiasis in people with ADPKD should be the same as that used in the general population. Obstructing kidney stones should be managed by centers of expertise, as they are more challenging in ADPKD.

**Gout.** No evidence shows that gout is more common in ADPKD than in other forms of CKD. We agree with the recommendations from the *2020 American College of Rheumatology Guideline for the Management of Gout*.<sup>12</sup> People with ADPKD should not receive routine pharmacologic treatment for asymptomatic hyperuricemia. People with ADPKD and gout should be evaluated and treated taking into account their level of kidney function. People with onset of hyperuricemia and gout in childhood or adolescence should receive genetic testing for autosomal dominant tubulointerstitial kidney disease.<sup>8</sup>

**Hematuria.** Healthcare providers should discuss the possibility of, causes of, and natural history of gross hematuria with patients at the time of diagnosis of ADPKD, to avoid unnecessary worry when it happens.

**Urinary tract infections.** We agree that the recommendations for the general population from the *American Urological Association, the Canadian Urological Association, and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction*, for female pelvic medicine and urogenital reconstruction, also apply to people with ADPKD.<sup>13</sup> Healthcare providers should do the following: not treat asymptomatic bacteriuria; use first-line therapy (i.e., nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin), dependent on the local antimicrobial susceptibility profiles, for the treatment of uncomplicated, symptomatic urinary tract infections (UTIs) in women; obtain a urine culture before antibiotics are started; and treat people with recurrent UTIs experiencing acute cystitis episodes with as short a duration of antibiotics as is reasonable, generally no longer than 7 days. Following discussion with patients of risks, benefits, and alternatives, healthcare providers may prescribe antibiotic prophylaxis to decrease the risk of future UTIs in women previously diagnosed with UTIs.

Recurrent UTIs in people with ADPKD should be investigated for an underlying predisposition. Blood cultures should be obtained if an upper UTI or kidney cyst infection is suspected. UTIs in people with ADPKD should be differentiated from cyst hemorrhage or kidney stone. People with ADPKD who present with fever, acute abdominal or flank pain, and an increased white blood cell count and/or C-reactive protein level should undergo workup for kidney cyst infection (Figure 5).<sup>14</sup> We recommend 4–6 weeks of



**Figure 5 | Diagnostic algorithm for an infected kidney cyst in autosomal dominant polycystic kidney disease.** CT, computed tomography; <sup>18</sup>FDG PET-CT, positron emission tomography with <sup>18</sup>F-fluorodeoxyglucose integrated with computed tomography; Ga-67, Gallium-67; MRI, magnetic resonance imaging. Adapted from Lantinga et al.<sup>15</sup>

antibiotic therapy in people with ADPKD and kidney cyst infection. A lipid-soluble antibiotic (e.g., trimethoprim-sulfamethoxazole, fluoroquinolone) may have better penetration into the cysts, and should be used if possible. However, the use of fluoroquinolones has been associated with an increased risk for tendinopathies and aortic aneurysms and dissections.

**Renal cell carcinoma.** No clear association exists between ADPKD and an increased risk of renal cell carcinoma. However, healthcare providers should be aware of atypical presentation of renal cell carcinoma in people with ADPKD.

### Chapter 3: CKD management and progression, KF, and kidney replacement therapy

**CKD management and progression.** In general, the management of CKD in ADPKD is similar to that in other kidney diseases.<sup>16–19</sup> People with ADPKD tend to have a higher hemoglobin level, compared to that of people with other forms of CKD, due to regional hypoxia driving production of hypoxia-inducible transcription factors. Erythrocytosis (hematocrit level >51% or hemoglobin level >17 g/dl [170 g/l]) may occur in people with ADPKD, rarely before KF, and more frequently following kidney transplantation. Administration

of an ACEi or an ARB is usually the initial treatment for post-transplant erythrocytosis, with hematocrit and hemoglobin targets of <51% and <17 g/dl [170 g/l], respectively. Therapeutic phlebotomy is indicated when an ACEi or an ARB is contraindicated or is ineffective at a maximal-tolerated dose.

Management of diabetes in people with ADPKD should be the same as that for people with other forms of CKD. Due to lack of evidence, use of sodium-glucose cotransporter-2 inhibitors is not advised at this time. Preferred glycemic management strategies are use of metformin when eGFR is ≥30 ml/min per 1.73 m<sup>2</sup>, or a glucagon-like peptide-1 receptor agonist when eGFR is <30 ml/min per 1.73 m<sup>2</sup>, when metformin is not tolerated, or when treatment with metformin alone is not sufficient for optimal glycemic control.

For the primary prevention of cardiovascular disease, lipid-lowering therapy should be initiated, in line with the *KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease*.<sup>19</sup>

**Kidney transplantation.** Kidney transplantation, preferably preemptive, living-donor kidney transplantation, is the preferred treatment for KF for people with ADPKD. During the pretransplantation workup, estimated total kidney and liver weights derived from total kidney and liver volumes

should be subtracted from the body weight, for an accurate assessment of body mass index. Pretransplant evaluation should consider performing imaging of the kidneys within 1 year prior to the anticipated timing of transplantation, to rule out solid or complex cystic lesions. Immunosuppressive protocols should be the same as those used for other transplant recipients.

Native nephrectomy should be performed only for specific indications and when the benefit outweighs the risk. Potential indications include severe symptoms from massively enlarged kidneys, recurrent or severe kidney infection or bleeding, complicated nephrolithiasis, intractable pain, suspicion of renal cell carcinoma, insufficient space for the kidney graft, and severe ventral hernia. Nephrectomy should occur either at the time of or after transplantation, but not before, due to the potential need for transfusion, preventing preemptive transplantation, and the increased risk of complications. The type of nephrectomy should be hand-operated laparoscopic nephrectomy, rather than open nephrectomy. The choice between unilateral versus bilateral native nephrectomy will depend on providers' clinical judgment and the availability of local expertise.

New-onset diabetes, erythrocytosis, worsening aortic, tricuspid, or mitral regurgitation, aortic root dilatation, subarachnoid hemorrhage, thromboembolic events, skin cancers, kidney or liver cyst infections, and colon diverticulitis were more common in some studies of kidney transplant recipients with ADPKD than they were in the general kidney transplant population.

**Chronic dialysis.** Shared decision-making, prescription of hemodialysis, and supportive therapies, such as anticoagulation, should be the same as those for people without ADPKD.<sup>20</sup> Peritoneal dialysis should be considered as a viable option, with caution used when massive kidney and/or liver enlargement or abdominal wall hernias are present.

#### Chapter 4: Therapies to delay the progression of ADPKD

Interventions targeting the action of the antidiuretic hormone arginine vasopressin on the vasopressin-2 receptor in the kidney cystic epithelium are presently the cornerstone of treatment in people with ADPKD at risk of rapid kidney disease progression.

**Tolvaptan.** Our systematic review found 3 RCTs of tolvaptan, an antagonist of the vasopressin-2 receptor, together with 2 extension studies; a pooled, matched comparison of long-term tolvaptan-treated and untreated groups; and a post marketing analysis of harms. Overall, the evidence review found a net difference in eGFR decline of 1.3 ml/min per 1.73 m<sup>2</sup> per year (95% confidence interval: 1.0–1.7) and in total kidney volume growth of –2.7% (95% confidence interval: –3.3% to –2.1%), both favoring tolvaptan use. The incidences of UTI, kidney stones, hematuria, and kidney pain events were significantly reduced in the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 trial. The effect of

tolvaptan on the rate of eGFR decline is accepted as a reliable surrogate for delaying the onset of KF.<sup>21,22</sup>

We recommend initiating tolvaptan treatment in adults with ADPKD with an eGFR  $\geq 25$  ml/min/1.73 m<sup>2</sup> who are at risk for rapidly progressive disease.

The definition of risk of rapidly progressing ADPKD was determined largely by clinical consensus. We advise using the MIC, ideally based on MRI, as the primary method for risk prediction and consideration of tolvaptan use in clinical care. Low-dose CT is an alternative to determine the MIC. When MRI and CT are not available or are contraindicated, employing ultrasound using the ellipsoid formula is acceptable. The historical decline in eGFR also can be used in the absence of advanced imaging. An annual eGFR decline  $\geq 3$  ml/min per 1.73 m<sup>2</sup>, as determined by multiple measurements of eGFR over 3–5 years, or a Predicting Renal Outcome in PKD score  $>6$ , may provide evidence for risk for rapid progression.


Contraindications to tolvaptan use should be considered before initiating such treatment.<sup>21,22</sup> Absolute contraindications include the following: a planned pregnancy; pregnancy; breastfeeding; medical conditions associated with a high risk of volume depletion; inability to respond to or perceive thirst; hyponatremia; urinary tract obstruction; strong cytochrome P450, family 3, subfamily A inhibitors; and significant liver disease, unless due to PLD. Relative contraindications to be considered include the following: an eGFR at initiation of  $<25$  ml/min per 1.73 m<sup>2</sup>; a history of gout or hyperuricemia; cytochrome P450, family 3, subfamily A inhibitors; P-glycoprotein inhibitors; grapefruit and Seville orange consumption; and urinary incontinence.<sup>21,22</sup>

We suggest using shared decision-making when deciding to initiate tolvaptan use in people aged  $>55$  years who have rapid kidney disease progression.

Physicians should be educated on the adverse effects, contraindications, and drug interactions of tolvaptan.<sup>21,22</sup> The aquaretic effects of tolvaptan require the need to drink enough water to replace urinary losses, to ensure long-term tolerability. Tolvaptan treatment should be interrupted in situations causing volume depletion or an inability to compensate for the aquaresis. Tolvaptan causes a small, reversible reduction in eGFR, likely reflecting its impact on compensatory hyperfiltration.

People with ADPKD should have a “sick-day plan” and be advised to skip doses of tolvaptan in situations in which they are at risk of volume depletion, such as those with limited access to water, those with increased fluid losses, and activities in warm weather. Individual adjustments should include adapting the schedule, timing, and doses of tolvaptan to the person's activities. Patients should be counseled to drink liquids without sugar or fat, and to adopt a low-sodium intake, because low osmolar intake reduces polyuria.

Tolvaptan should be initiated with a daily dose of 45 mg upon waking, and of 15 mg 8 hours later; this should be titrated gradually by the treating physician to permit adequate




**Figure 6 | Commencement of and titration approach to tolvaptan use in autosomal dominant polycystic kidney disease.** \*Examples of strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors (reduce clearance by >80%) are as follows: antifungals (itraconazole, ketoconazole); antibiotics (clarithromycin); and protease inhibitors (saquinavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, tipranavir). Examples of moderate CYP3A inhibitors (reduce clearance by 50%–80%) are as follows: antiarrhythmics (amiodarone); antifungals (fluconazole); antibiotics (erythromycin); calcium-channel blockers (diltiazem, verapamil); protease inhibitors (amprenavir, fosamprenavir); and complementary and/or dietary agents, such as grapefruit juice (240 ml coadministration).

adaptation to the aquaresis (Figure 6).<sup>21,22</sup> Monitoring through uptitration should include kidney function, blood electrolyte (sodium), and liver function test (LFT) levels in morning blood samples should be obtained before the dose of tolvaptan is taken. Serum sodium levels provide insight into the adequacy of water intake. Tolvaptan use can be continued in people aged >55 years and/or when the eGFR falls below 25 ml/min/1.73 m<sup>2</sup>, if it is well tolerated.

Tolvaptan use is associated with an increased risk for idiosyncratic drug-induced liver injury. Approximately 5% of people with ADPKD treated with tolvaptan, compared to 1% of people receiving placebo, in RCTs displayed an increase in transaminase levels that was above 3-fold the upper limit of normal. The increases in alanine transaminase level occurred most often during the first 18 months of treatment and resolved within 1–4 months after tolvaptan cessation.

Frequent monitoring (monthly for the first 18 months, and then every 3 months until drug discontinuation) of LFTs is mandatory in people treated with tolvaptan for ADPKD. Following regulatory approval by the United States (U.S.) Food and Drug Administration, all physicians prescribing tolvaptan for ADPKD in the U.S. must be trained and certified to appropriately apply the Risk Evaluation and Mitigation Strategies (REMS) program, whereas the European Medicines Agency has implemented a risk-management plan that includes education of both prescribing physicians and people with ADPKD.

The management of abnormal LFTs detected during tolvaptan treatment should be conducted according to local regulatory guidelines and product information (Figure 7). The administration of tolvaptan should be held, other possible etiologies considered, and LFTs rechecked within



**Figure 7 | Algorithm summarizing recommendations for evaluation and management of potential tolvaptan-induced liver injury.** ALT, alanine transaminase; AST, aspartate aminotransferase; LFT, liver function test; ULN, upper limit of normal. Reproduced from Chebib et al.<sup>21</sup>

48–72 hours if an elevation occurs in alanine transaminase or aspartate aminotransferase levels to  $>2\times$  the upper limit of normal or  $>2\times$  baseline values. Rechallenge after the LFTs return to normal can be considered, with increased monitoring in people who had mild transaminase-levels elevations. Per the U.S. label, tolvaptan should not be restarted in people who have had signs or symptoms consistent with hepatic injury or an alanine transaminase or aspartate aminotransferase level that is  $>3\times$  the upper limit of normal, unless another explanation accounts for the liver injury.

Additional side effects of tolvaptan include hyperuricemia, and rarely gout.

**Water intake in the absence of tolvaptan.** We suggest adapting water intake, spread throughout the day, to achieve an intake of at least 2–3 liters of water per day in people with ADPKD, and an eGFR  $\geq 30$  ml/min per  $1.73\text{ m}^2$ , without contraindications, such as medication use that may increase the risk of hyponatremia (e.g., serotonin reuptake inhibitors, tricyclic antidepressants, thiazide diuretics).<sup>21,22</sup>

**Other pharmacologic interventions.** We recommend not using mammalian target of rapamycin inhibitors, or metformin (in people who do not have diabetes), to slow the rate of disease progression in ADPKD. We recommend not using statins specifically to slow kidney disease progression. Somatostatin analogues should not be prescribed for the sole purpose of slowing eGFR decline, but their use can be considered in people with severe symptoms due to massively enlarged kidneys, to lower the growth rate of kidney cysts when no better options are available. We suggest not using sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists to slow the rate of eGFR decline, until further research determines their efficacy and safety. We suggest not using ketogenic interventions to slow the progression of ADPKD, without further evidence of their efficacy and safety in long-term trials. Complementary medicines or supplements should not replace standard medical treatments in people with ADPKD and should be discussed with the healthcare team.

## Chapter 5: Polycystic liver disease

Although in the majority of people with ADPKD, the number of liver cysts increases with age, most people will not develop clinically symptomatic PLD. Liver cysts, even in advanced PLD, do not usually impact the synthetic or secretory capacity of the liver. However, symptoms can ensue due to the mass effect of a large cystic liver exerting pressure on the diaphragm and abdominal wall, compressing other abdominal organs and vascular structures. Multiple classification and staging systems based on liver volume (LV) and cyst characteristics have been proposed to plan management and monitor severity of PLD.<sup>4,6,23</sup>

**Diagnosis and staging of PLD.** The liver should be included in abdominal imaging, using MRI, CT scan, or if

these are not available, ultrasonography, to obtain LV and characterize the severity of PLD. People should be advised of the likely outcomes and possible symptoms of PLD. Symptoms of PLD should be captured with specific questionnaires.

**Risk factors.** PLD occurs at earlier ages and with more-aggressive cyst growth in women than in men. Women with ADPKD, particularly those with PLD, should be counseled about the benefits and potential harms of receiving sex hormone therapy. Exposure to estrogen-containing oral contraceptives, as well as estrogen-replacement therapy, was associated with a greater LV, and an annual increase in LV, in several studies of women with ADPKD.

**Nutrition and lifestyle.** People with symptomatic PLD should be assessed for sarcopenia and malnutrition. People with sarcopenia or malnutrition should be provided with intensive nutrition counseling and exercise rehabilitation.

**Management of PLD.** Treatment for PLD should be performed in centers of expertise. People with cyst-related symptoms or complications that impact their quality of life should be treated. The type of treatment should be based on symptoms, liver cyst characteristics, total LV, and available expertise (Table 3).<sup>4,23</sup>

We recommend prescribing long-acting somatostatin analogues in people with marked cystic hepatomegaly in PLD with severe volume-related symptoms. Long-acting somatostatin analogues (e.g., octreotide, lanreotide, pasireotide) reduced 3',5'-cyclic adenosine monophosphate levels in cystic cholangiocytes, and inhibited cholangiocyte cell proliferation and fluid secretion. Four RCTs assessed the effect of somatostatin analogues on PLD, with a follow-up period of  $\geq 1$  year. They all reported a significant reduction in the rate of LV growth. The effect on symptom burden and/or volume of polycystic liver and kidneys should be evaluated after 6–12 months. When beneficial effects of therapy are not observed, use of somatostatin analogues should be discontinued.

People with PLD should be referred for liver transplantation in the event of massive PLD, in the absence of contraindications or alternative treatment options. People with PLD should be referred for combined kidney–liver transplantation when an indication is present for liver transplantation and the kidney function is severely impaired (eGFR  $<30$  ml/min per  $1.73\text{ m}^2$ ).

**Liver cyst infections.** Diagnosis of liver cyst infections should utilize clinical signs and symptoms, microbiology, and advanced imaging such as MRI or 2-deoxy-2-fluorine-18-fluoro-D-glucose positron emission tomography–computed tomography. Pain and tenderness over the liver, and history of biliary instrumentation, help to differentiate it from kidney cyst infection (Figure 8). Imaging studies should be performed to determine the severity and location of a liver cyst infection. Fever  $>38^\circ\text{C}$ , abdominal pain, an



**Table 3 | Treatment options for PLD**

| Treatment option                                      | Liver phenotype indication   | Efficacy  | Morbidity and mortality  |
|---|--|---|--|
| Aspiration sclerotherapy                              | One or few large dominant cysts, symptomatic or causing compression of veins or bile ducts   | Symptomatic improvement: 72%–100%<br>Individual cyst volume reduction: 76%–100%                                 | Minor complications: 5%–90%<br>Mortality: <1.0% (none reported)  |
| Transarterial embolization                            | Diffuse symptomatic cysts, at least one segment of functioning liver, no alternative treatment options                                       | Symptomatic improvement: 72%–93%<br>Need for reintervention: 15%<br>Reduction in TLV: 13% at 3 mo; 28% at 51 mo | Postembolization syndrome: 100%<br>Complications: 7.5%   |
| Laparoscopic cyst fenestration                        | Large symptomatic liver cysts located anteriorly and caudally  | Symptomatic recurrence: 34%<br>Need for reintervention: 26%   | Complications: 29%<br>Clavien III–IV <sup>a</sup> perioperative complications: 7.2%<br>Mortality: 2.3%   |
| Combined partial hepatectomy and/or cyst fenestration | Massive, highly symptomatic PLD, at least one hepatic sector relatively spared, patent afferent and efferent sectoral vasculature            | Reduction in TLV: 61% postoperative and at 8 yr<br>Symptomatic improvement: 94%                                 | Clavien III–IV perioperative complications: 21%<br>Mortality: 2.7%<br>Survival: 96%, 93%, 86%, and 78% at 1, 5, 10, and 15 yr  |
| Liver transplantation                                 | Massive PLD and high symptom burden or sarcopenia or PLD-related complications, contraindication or failure of alternative treatment options | Only curative treatment option  | Postoperative complications: 46%<br>Mortality: 9%<br>1-yr patient survival: 85%–95%<br>5-yr patient survival: 77%–92%  |
| Somatostatin analogues                                | Severe, symptomatic hepatomegaly   | Reduction in annual liver growth rate of 6%–15% after 1–3 yr of follow-up                                       | Dose adjustments for side effects (e.g., GI complaints or hyperglycemia)<br>Gallstones<br>Bradycardia<br>Rarely cyst infections<br>Pasireotide has high hyperglycemia risk |


GI, gastrointestinal; PLD, polycystic liver disease; TLV, total liver volume.

<sup>a</sup>Clavien grade III complications require surgical, endoscopic, or radiologic intervention. Clavien grade IV complications are life-threatening and require intensive-care management.

elevated serum C-reactive protein level of  $\geq 50$  mg/l, and elevated white blood cell counts are highly suggestive of a liver cyst infection. Empiric antibiotics should not be used to treat people with localized liver pain without fever who have normal white blood cell counts and C-reactive protein levels. Other causes of pain, such as cyst hemorrhage, should be considered.

Empiric antibiotic treatment of liver cyst infections should target gram-negative *Enterobacteriaceae* bacteria, using a third-generation i.v. cephalosporin, with or without a fluoroquinolone. After clinical stabilization, i.v. therapy can be switched to an oral fluoroquinolone, with adjustment according to culture results when available. Duration of antibiotic therapy should be  $\geq 4$  weeks for liver cyst

infection, and longer treatment periods may be required based on the response to therapy. An approach that may be reasonable is to perform percutaneous drainage of infected liver cysts when pathogens unresponsive to antibiotic therapy are isolated from a cyst aspirate, in cases of the following: isolation from a cyst aspirate of pathogens that are unresponsive to antibiotic therapy; immunocompromise; large infected hepatic cysts ( $>8$  cm); hemodynamic instability, and/or signs of sepsis. The percutaneous drain should be kept in place until drainage stops. In the case of deep cysts for which percutaneous drainage is not feasible, surgical drainage may be necessary. Infected liver cysts that do not respond to 48–72 hours of antibiotic treatment should be evaluated further.



**Figure 8 | Management of liver cyst infections in autosomal dominant polycystic kidney disease.** CRP, C-reactive protein.

## Chapter 6: Intracranial aneurysms (ICAs) and other extrarenal manifestations

**ICAs.** People with ADPKD have an increased risk for ICAs and aneurysmal subarachnoid hemorrhage (SAH), compared to the general population.<sup>24</sup> The vast majority of aneurysms in people with ADPKD do not rupture. The potential benefit of presymptomatic screening and preemptive intervention to prevent aneurysmal rupture depends on the following: the prevalence of ICA; the risk of rupture with medical therapy alone; the yield and risk of the screening technique; the rate of complications associated with strategies employed for preventive occlusion, as well as their technical success rate; and the risk of aneurysm recurrence and *de novo* aneurysm development and rupture. Potential implications of detecting an intracranial vascular abnormality on imaging (e.g., eligibility for life insurance), as well as anxiety, notably when preventive occlusion is not indicated, should be

considered. Ethnic and local differences and possible effects of improved BP control and reduction in smoking on the declining incidence of SAH in the general population also need to be considered.

We recommend informing adults with ADPKD about the increased risk for ICA and SAH, including risk factors, screening, preventive measures, and symptoms that should trigger immediate medical attention. All people with ADPKD should be educated to recognize thunderclap headache, characterized by a sudden onset of severe headache that reaches its maximum intensity within seconds to a minute. Signs of an aneurysmal rupture should prompt immediate medical attention. Because smoking is a strong modifiable factor for ICA development and rupture, healthcare providers should ask all people with ADPKD about their tobacco use, advise them to stop using tobacco, and provide behavioral interventions and approved

pharmacotherapy for cessation, if needed. Because uncontrolled hypertension is a modifiable risk factor for ICA development and rupture, hypertension should be diagnosed early and treated adequately in people at risk of or diagnosed with ADPKD.

We recommend screening for ICA in people with ADPKD and a personal history of SAH or a positive family history of ICA, SAH, or unexplained sudden death if the person will be eligible for treatment and has a reasonable life expectancy. Screening for unruptured ICA should be discussed in people with *de novo* ADPKD, those with unknown or unclear familial history, and those with personal or familial history of extracerebral vascular phenotype. Screening also may be considered in specific clinical settings, such as during evaluation for kidney and/or liver transplantation, or before major elective surgery. People with ADPKD who are not considered at increased risk for ICA and who, after being given comprehensive information, prefer being screened for ICA, should be given access to screening. In women in whom screening is indicated or considered for the reasons stated above, screening for ICA should be discussed before pregnancy.

Time-of-flight magnetic resonance angiography without gadolinium enhancement should be the method of screening for ICA in people with ADPKD. High-resolution CT angiography can be an alternative. If the screening is negative in people with a high risk of ICA, the timing of rescreening should be individualized to every 5–10 years, based on risk factors, age, and life expectancy. When one or several ICAs are identified, treatment options, such as conservative management and microvascular or endovascular repair, should be assessed within a multidisciplinary

setting at centers of expertise that have high volumes of ICA cases.

**Other vascular associations.** Routine screening of vascular abnormalities of nonintracranial large arteries has no role in people with ADPKD and no familial history of vascular aneurysms or dissections. In cases of familial history of aortic root or thoracic aortic aneurysms in people with ADPKD, screening of first-degree relatives should be performed. In people with ADPKD and dilatation of the aortic root or thoracic aortic aneurysm, therapeutic measures to limit aortic expansion should include smoking cessation, statin therapy, and antihypertensive therapy, including a beta-blocker and/or an ACEi or ARB.

**Cardiac associations.** Echocardiography at baseline and/or during follow-up should be considered in people with ADPKD who have the following: a history of severe or uncontrolled hypertension; heart murmur, signs or symptoms of cardiac dysfunction, or other cardiovascular manifestations; or a familial history of thoracic aortic aneurysm or non-ischemic cardiomyopathy.

**Abdominal wall hernia.** In people with asymptomatic abdominal wall hernias and severe kidney enlargement and/or KF, nonsurgical management should be discussed, because of the increased risk for complications associated with repair and because of potential hernia recurrence. People with ADPKD managed expectantly for abdominal wall hernia should be educated to recognize symptoms of hernia incarceration or strangulation, which should lead to prompt surgical evaluation. Surgical repair of abdominal wall hernias should be considered in people with ADPKD who elect peritoneal dialysis as a mode of kidney replacement therapy.

**Other extrarenal manifestations.** ADPKD is a systemic disorder with additional manifestations in multiple tissues ([Table 4](#)).

**Table 4 | Extrarenal manifestations associated with ADPKD**

| Extrarenal manifestations                      | Estimation of people with ADPKD affected, % | Details and/or notes  |
|--|---|---|
| Intracranial aneurysm                          | 12.9  | Prevalence in ADPKD population is difficult to assess because systematic screening usually is not performed.  |
| Subarachnoid hemorrhage                        | Incidence rate 0.57 per 1000 patients/yr    | Thunderclap headache should lead to immediate medical attention.  |
| Intracranial arterial dolichoectasia           | ~0.7–5                                      | Dolichoectasia (dilatative arteriopathy) is usually asymptomatic, but may cause stroke, and may mimic ICA on imaging studies.   |
| Arachnoid cyst                                 | 8–15  | Usually asymptomatic, incidental diagnosis<br>Possible increased risk of spontaneous subdural hematoma  |
| Meningeal cyst                                 | Rare  | Usually asymptomatic, incidental diagnosis<br>May very rarely cause spontaneous intracranial hypotension  |
| Mitral valve prolapse and regurgitation        | 3–26  | Usually asymptomatic<br>MVP was formerly reported to be present in 20%–30% of people with ADPKD, but more recent studies using current definition of MVP reported prevalence of 1% in pediatric and 3.4% in adult cohorts, similar to prevalence in the general population. |
| Pericardial effusion                           | ~20   | Usually asymptomatic, incidental diagnosis  |
| Cardiomyopathy                                 | Rare  | Hypertrophic cardiomyopathy: 2.5% <sup>a</sup><br>Dilated cardiomyopathy: 5.8% <sup>a</sup><br>Left ventricular noncompaction: 0.3%   |
| Congenital heart malformation                  | Rare  | Very rare case-series and case reports<br>Left-to-right shunt, obstructive cardiomyopathies, and other complex malformations reported   |
| Situs inversus and large vessels transposition | Rare  | Laterality defects including dextrocardia and situs inversus totalis have been reported in a small number of people with ADPKD, mostly PKD2.  |
| Thoracic aortic aneurysm                       | ~1.5  |   |
| Thoracic aortic dissection                     | Rare  | Acute chest/upper back/abdominal pain is present in >90% of the cases.  |
| Coronary arteries dissection                   | Rare  | Symptoms of acute myocardial infarction<br>Usually more frequent in young women   |
| Carotid and vertebral artery dissection        | Rare  | Often result in ischemic stroke or transient ischemic attack, often associated with neck pain or headaches. Occasional Horner syndrome in cases of carotid dissections  |
| Retinal artery and vein occlusion              | Rare  | Single case-series of 8 people with ADPKD   |
| Symptomatic polycystic liver disease           | <5, predominant in females                  | Liver cysts are present in >80% by age 30 yr.   |
| Congenital hepatic fibrosis                    | Rare  | More common in ARPKD  |
| Pancreatic cysts and IPMN                      | Pancreatic cysts ~10                        | Complex or multiple pancreatic cysts should be followed and evaluated to exclude malignancy, particularly Von Hippel–Lindau syndrome.   |
| Splenic cysts                                  | ~7  | Like general population; usually asymptomatic, incidental diagnosis   |
| Abdominal wall hernia                          | Common                                      | Published evidence from a small cohort in Wales, but very common clinical finding   |
| Dilated extrahepatic bile duct                 | ~40   | Small cohort single study   |
| Colonic diverticulosis                         | 1.5   | Single, large national database   |
| Duodenal or small-bowel diverticula            | Rare  | Rarely, periampullary duodenal diverticula may be associated with obstructive jaundice or ascending cholangitis.  |
| Bronchiectasis                                 | 19–37                                       | Incidental radiologic finding, typically of no clinical significance  |
| Pleural effusion                               | 21 vs. 8 in controls                        | Incidental radiologic finding, more frequent in females, not clinically significant   |
| Sperm abnormality                              | Abnormal semen parameters reported          | May be associated with male infertility, although no large study has demonstrated that male infertility was more common in ADPKD  |
| Seminal vesicle cysts                          | 20–40                                       | Although commonly identified, seminal vesicle cysts do not result in male infertility.  |
| Seminal vesicle ectasia                        | Ectasia >10 mm: 23                          | Although commonly identified, seminal vesicle ectasia does not result in male infertility.  |

ADPKD, autosomal dominant polycystic kidney disease; ARPKD, autosomal recessive polycystic kidney disease; CKD, chronic kidney disease; ICA, intracranial aneurysm; IPMN, intraductal papillary mucinous neoplasms; MVP, mitral valve prolapse.

<sup>a</sup>Likely referral bias, estimates taken from a single study and should be interpreted with caution.

## Chapter 7: Lifestyle and psychosocial aspects

Healthcare providers need to provide people with ADPKD with advice and guidance regarding nutrition, lifestyle, physical activity, and management of psychosocial issues. Care can be provided by the core multidisciplinary team or by referral to dedicated services.

**Nutrition.** People with ADPKD should follow the general advice for a healthy diet, consistent with World Health Organization and CKD guidelines, and should work with accredited nutrition providers or registered dietitians to receive individualized counseling, particularly people with CKD G4–G5, those at high risk of urinary stones, those who are overweight (body mass index, 25–29.9 kg/m<sup>2</sup>) or obese (body mass index, >30 kg/m<sup>2</sup>), and those with malnutrition or sarcopenia.<sup>25</sup> The estimated weight of cystic kidneys should be taken into consideration when calculating the body mass index.

**Physical activity.** Adults with ADPKD should be encouraged to undertake moderate-intensity physical activity, for a cumulative duration of at least 150 minutes per week or to a level compatible with their cardiovascular and physical tolerance, and strength training at least 2 sessions per week. People with large kidneys and/or liver should be advised of the possibility of direct injury during physical activity and exercise. Expert consultation is advisable in prescribing exercise for people with cardiovascular disease, frailty or risk of falling, bone disease, or who are on dialysis or are post-transplantation.

**Lifestyle management.** All people with ADPKD should be asked about the following: their use of tobacco products, all of which should be avoided; their use of alcohol, with the recommendation that they consume ≤1 alcoholic drink per day, for females, and ≤2 drinks per day, for males; caffeine intake, with advice to avoid excessive caffeine intake, particularly during pregnancy; cannabis products, with counseling about the potential dangers of acute kidney injury related to product contamination and synthetic versions; and recreational drugs and anabolic steroids, with advice to refrain from these drugs.

**Psychosocial care.** Healthcare providers should screen for and conduct periodic assessment of psychosocial issues. Key stressors related to ADPKD include those that are physical, social, related to family members, and related to the inherited nature of the disease. Education programs to promote self-management should be implemented to provide comprehensive and practical information to people and their families. People should be informed about patient organizations dealing with PKD or kidney disease in general, and other support and advice services. The healthcare team should discuss with patients and their caregivers the financial impacts of having ADPKD and try to help patients avoid unnecessary medical expenses.

## Chapter 8: Pregnancy and reproductive issues

Healthcare for women with ADPKD of childbearing age includes management of hormonal therapies, contraceptive measures, preconception counseling, and pregnancy management.

**Contraceptive measures in women.** Given that estrogen, and possibly progesterone, exposure may be associated with an increased risk of PLD progression, women with ADPKD and liver cysts should be educated regarding their contraceptive choices.<sup>26</sup> When hormone therapy is being considered in women with ADPKD, liver imaging should be made available to inform discussion. Estrogen oral contraceptives may aggravate PLD, whereas the impact of combined estrogen and/or progestin oral contraceptives, patches, and vaginal rings on PLD is not known. The impact of progestin-only methods (pills, injections, implants, and intrauterine devices) on PLD is not known, but the level of systemic exposure with levonorgestrel-releasing intrauterine devices is low (4%–13% of that with use of combined oral contraceptives). People without or with mild PLD can use combined low estrogen and/or progestin contraceptives. Progestin-only intrauterine devices are likely safe for people with moderately severe PLD. Nonhormonal methods (barrier-based and copper intrauterine devices) are safest for people with severe PLD. Contraception in adolescents or young adults with ADPKD should not be restricted.


**Preconception counseling.** Preconception counseling should be offered to both men and women with ADPKD, to discuss options to prevent transmitting ADPKD to future children.<sup>23</sup> The counseling should be provided by a multidisciplinary team in an ADPKD referral center when possible and should include all available reproductive options (Figure 9). Use of renin–angiotensin system inhibitors, tolvaptan, and any other teratogenic drug should be stopped prior to the start of pregnancy and not restarted until the mother has completed breastfeeding. Although men with ADPKD show an increased prevalence of seminal tract cysts and sperm abnormalities, these do not appear to impact fertility.

**Pregnant women with ADPKD.** Pregnant women with ADPKD should be followed by a multidisciplinary team in an expert center.<sup>27</sup> During pregnancy, BP, kidney function, the soluble fms-like tyrosine kinase-1-to-placental growth factor ratio (if available), and proteinuria should be monitored. Pregnant women with ADPKD should undergo monthly urinalysis; in the case of a positive urine culture, even when patients are asymptomatic, they should be treated with appropriate antibiotics, as used during pregnancy in the general population. Women with ADPKD can safely perform vaginal delivery. When a pregnant woman with ADPKD experiences acute abdominal pain, imaging can be performed safely with either ultrasound or MRI.

More frequent BP monitoring, preferably weekly home BP monitoring, should be advised, particularly in cases of pre-existing hypertension or hypertension diagnosed during pregnancy. Antihypertensive medications to control BP during pregnancy (i.e., labetalol, nifedipine long-release, hydralazine, clonidine, or methyldopa) can be used when indicated in women with ADPKD. The BP target in pregnant women with ADPKD is ≤130/85 mm Hg.

Pregnant women with ADPKD should be monitored, because of an increased risk of preeclampsia and preterm





**Figure 9 | Reproductive options for men and women with autosomal dominant polycystic kidney disease (ADPKD).**

delivery.<sup>28</sup> Assessment of the soluble fms-like tyrosine kinase-1-to-placental growth factor ratio in plasma, from 24 weeks of gestation (earlier in patients with history of early pre-eclampsia in a previous pregnancy), and every 4–6 weeks, should be done for prediction of and to rule out pre-eclampsia. Low-dose aspirin should be prescribed from week 12 to week 36 in pregnant women with ADPKD.

Mild radiographic kidney abnormalities in the fetal kidneys do not necessarily predict a severe outcome. Shared decision-making regarding the value and implications of confirmatory genetic testing is advised. Severe fetal bilateral structural kidney cystic disease and/or oligohydramnios portend a higher risk of a poor neonatal outcome or early-onset childhood kidney dysfunction. A normal fetal ultrasound does not exclude the diagnosis of ADPKD in an at-risk child.

Women with ADPKD should be seen by a nephrologist early (at 6 weeks) and within 6 months after delivery, for a postpartum kidney review. Women with ADPKD may have bladder instability or urinary incontinence after delivery and should be offered pelvic-floor physical therapy.

## Chapter 9: Pediatric issues

Currently, no validated stratification models have been developed to identify children at risk of rapid progression, and no approved therapies are available for specifically this population.

**Diagnosis of ADPKD in children.** ADPKD may begin antenatally or in early childhood. Diagnoses of very early-onset ADPKD (clinical abnormalities due to ADPKD before age 18

months) and early-onset forms of ADPKD (between ages 18 months and 15 years) are rare and are distinct subentities of ADPKD.

Shared decision-making should be undertaken when discussing the benefits and harms related to the screening and/or diagnosis of at-risk children in families with ADPKD, including the parents and/or legal guardians and the mature child.<sup>26</sup> Expert counseling about diagnostic options, delivered by a team that includes a pediatric nephrologist and a geneticist, should be offered. Ultrasound should be the preferred imaging method. People and families should be informed that the presence of a single kidney cyst in an at-risk child (aged <15 years) is highly suspicious for the diagnosis of ADPKD, but that the absence of cysts does not rule out ADPKD.

Ultrasound of the parents (or the grandparents, if the parents are aged <40 years) should be considered when seeking a diagnosis in children with incidentally detected kidney cysts and negative family history for ADPKD, with the goal of detecting an unknown family history. The possibility of a benign simple cyst should be included in the differential diagnosis of children with an isolated cyst, a negative family history, and a negative workup of the parents or grandparents. Genetic testing should be offered for children with very-early-onset ADPKD or an atypical presentation of ADPKD, or with cystic kidneys and a negative familial history of ADPKD, or in the context of screening at-risk children after a shared decision has been made.

**BP control in children and adolescents with ADPKD.** Standardized office BP measurement should be performed annually in

children (aged  $\geq 5$  years) and adolescents with or at risk for ADPKD. Annual 24-hour ambulatory BP-monitoring should be performed in children and adolescents (aged  $\geq 5$  years; height  $\geq 120$  cm) with very-early-onset ADPKD or early-onset ADPKD, and in children and adolescents with or at risk for ADPKD with BP at  $\geq 75$ th percentile.<sup>29</sup> If ambulatory BP-monitoring is not available, routine in-office or home BP-monitoring are acceptable alternatives. Evaluation of high BP in children and adolescents with or at risk for ADPKD should include consideration of the possibility of primary or other secondary causes of hypertension. Echocardiography to exclude left ventricular hypertrophy should be performed in children and adolescents with ADPKD and high BP. High BP should be managed by a pediatric nephrologist.

We recommend targeting BP to be at  $\leq 50$ th percentile for age, sex, and height, or  $\leq 110/70$  mm Hg in adolescents in the setting of ADPKD and high BP, and using renin-angiotensin system inhibitors (i.e., ACEi or ARBs) as the first-line therapy for high BP in children and adolescents with ADPKD.

**Follow-up assessment in children with ADPKD.** Monitoring of kidney disease progression in children with ADPKD should be tailored based on clinical indications, BP, kidney function, urine studies, and ultrasound findings. Routine screening for extrarenal manifestations is not advised, but screening should be performed when concerning symptoms are present. UTI in children with ADPKD should be managed the same as UTI in children without ADPKD. Ultrasound examination should be performed with atypical courses of UTIs, to rule out cyst infection. Abdominal pain, nephrolithiasis, and proteinuria in children with ADPKD should be managed the same as those in children without ADPKD. Vasopressin analogues should

not be used to treat nocturnal enuresis in children with or at risk of ADPKD.


**Diet and lifestyle in children with ADPKD.** Children with ADPKD should follow general recommendations for a healthy diet, consistent with World Health Organization guidelines, and should maintain a healthy body weight and levels of physical activity. Children with ADPKD and hypertension or CKD should follow the same recommendations for diets and physical activities as those for all children with hypertension or CKD.

**Optimal models of care for children with ADPKD.** Currently, the evidence is insufficient to support use of disease-modifying therapies for ADPKD in children, beyond antihypertensive treatment.<sup>30</sup> A formal transition process for entering young adulthood should be developed for all children diagnosed with or at risk for ADPKD.

## Chapter 10: Approaches to the management of people with ADPKD

Shared decision-making should be the cornerstone of patient-centered management in people with ADPKD. The lifelong management of people with ADPKD should follow a comprehensive, multidisciplinary, and holistic care pathway (Figure 10).<sup>31,32</sup>

People with ADPKD should be encouraged and enabled to participate in registries, cohort studies, and clinical trials testing novel diagnostic or therapeutic approaches (including novel agents, repurposed drugs, or combinations of agents). Healthcare systems should provide care coordination and/or patient navigation for people with ADPKD along their care pathways. Healthcare systems should implement a self-management program for people with ADPKD, taking into consideration the local and cultural context, and the



**Figure 10 | A proposed autosomal dominant polycystic kidney disease (ADPKD) care pathway.** Ultrasound-based kidney imaging, including kidney length measurements, could be considered if MRI or computed tomography are not routinely available. eGFR, estimated glomerular filtration rate; MRI, magnetic resonance imaging; PRO, patient-reported outcome; TKV, total kidney volume. Adapted from EAF Co-chairs et al.<sup>31</sup>; Mao et al.<sup>32</sup>; Ong et al.<sup>33</sup>

availability of resources. Healthcare systems should promote participation in registries for people with ADPKD, so that outcome data using standardized data definitions can be gathered. ADPKD-focused patient organizations, national kidney federations, and patient-support groups can help enhance the care of people with ADPKD and their families, through provision of general information and peer support (Supplementary Table S3).

## Conclusions

The *KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD* represents the first KDIGO guideline that focuses on a genetic disorder that affects millions of people worldwide and is a major cause of KF. Recent developments impacting all aspects of ADPKD, and the emergence of local guidelines and recommendations, justified the need for a global guidance document. The comprehensive KDIGO guideline, developed with clinicians, researchers, and patients from around the world, points to important aspects of living with ADPKD, for people at all ages, relating to diagnosis, definition, staging, management, and treatment, and taking into account the availability of resources. Specific aspects linked to the dominant mode of transmission of ADPKD are addressed. Our systematic review identified gaps in the knowledge base, and remaining controversies, which are integrated into a comprehensive research agenda. Together, these recommendations and practice points offer a strong basis to implement new approaches and therapies for people living with ADPKD and their families, following a comprehensive, multidisciplinary, and holistic care pathway.

## DISCLOSURE

The development and publication of this guideline were supported by Kidney Disease: Improving Global Outcomes (KDIGO). The opinions or views expressed in this summary are those of the authors and do not necessarily reflect the opinions or recommendations of the International Society of Nephrology or Elsevier. Dosages, indications, and methods of use for products that are referred to in the supplement by the authors may reflect their clinical experience or may be derived from the professional literature or other clinical sources. Because of the differences between *in vitro* and *in vivo* systems and between laboratory animal models and clinical data in humans, *in vitro* and animal data do not necessarily correlate with clinical results.

VET reports receiving consultancy fees from Janssen Pharmaceuticals\*, Mironid\*, Palladio Biosciences\*, and Vertex Pharmaceuticals\*; and research support from Blueprint Medicines\*, Mironid\*, Palladio Biosciences\*, Reata Pharmaceuticals\*, Regulus Therapeutics\*, Sanofi\*, and Tribune Therapeutics\*. MAC reports receiving consultancy fees from Otsuka Pharmaceutical. ABC reports receiving research support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Otsuka Pharmaceutical, Regulus Therapeutics, and UpToDate; and speaker honoraria from Cleveland Clinic, the National Kidney Foundation, and the Renal Physicians Association. JPHD reports receiving consultancy fees from Camurus\*; and research support from Camurus\* and Gilead Sciences\*.

RTG reports receiving consultancy fees from AstraZeneca\*, Bayer Healthcare Pharmaceuticals\*, Dutch Kidney Foundation\*, Dutch Heart Foundation\*, Galapagos\*, GlaxoSmithKline\*, Happitech\*, Health Holland\*, Ipsen\*, Mironid\*, Otsuka Pharmaceutical\*, Roche\*, and Sanofi-Genzyme\*; and research support from AstraZeneca\*, Bayer Healthcare Pharmaceuticals\*, Dutch Kidney Foundation\*, Dutch Heart Foundation\*, Galapagos\*, GlaxoSmithKline\*, Happitech\*, Health Holland\*, Ipsen\*, Mironid\*, Otsuka Pharmaceutical\*, Roche\*, and Sanofi-Genzyme\*. In addition, RTG reports owning the rights for the Orphan Medicinal Product Designation status for lanreotide. PCH reports receiving consultancy fees from Caraway Therapeutics\*, Janssen Pharmaceuticals\*, Maze Therapeutics\*, Mitobridge\*, Otsuka Pharmaceutical\*, PYC Therapeutics\*, Regulus Therapeutics\*, Renasant Bio\*, Sentynt Therapeutics\*, and Vertex Pharmaceuticals\*; and research support from Acceleron Pharma\*, Espervita Therapeutics\*, Jemincare\*, Merck\*, and Regulus Therapeutics\*. SH reports serving as a board member of Kyowa Kirin, Sanofi, and Welcia Holdings; receiving research support from Otsuka Pharmaceutical\*; and serving in the endowment department of Otsuka Pharmaceutical. MCL reports serving on an advisory board for Otsuka Pharmaceutical\*. AJM reports receiving research support from Medical Research Future Fund\*, National Health and Medical Research Council\*, PKD Australia\*, and Sanofi-Genzyme\*; serving on an advisory board for the Australian and New Zealand Society of Nephrology (unpaid) and GlaxoSmithKline (unpaid); serving as a site principal investigator for Dicerna Pharmaceuticals\*, Reata Pharmaceuticals\*, and Sanofi-Genzyme\*; and receiving travel expenses from Otsuka. DM reports receiving consultancy fees from Otsuka Pharmaceutical\*; and research support from Galapagos\* and Otsuka Pharmaceutical\*. DO reports receiving stock and stock options from Santa Barbara Nutrients, Inc. ACO reports receiving consultancy fees from Crinetics Pharmaceuticals\*, Galapagos\*, Janssen Pharmaceuticals\*, and Ono Pharmaceutical\*; serving on an advisory board for Mironid\*; and serving on a steering committee for Palladio Biosciences\* and Sanofi-Genzyme\*. LFO reports receiving consultancy fees from Otsuka Pharmaceutical; and serving on a steering committee for Palladio Biosciences\*. YPCP reports serving on an advisory board for Abbvie-Calico, AstraZeneca, BridgeBio, GlaxoSmithKline, Maze Therapeutics, and Otsuka Pharmaceutical. RDP reports receiving consultancy fees for AbbVie-Calico\*, Caraway Therapeutics, Janssen Pharmaceuticals\*, Navitor Pharmaceuticals, Otsuka Pharmaceutical\*, and Rex\*; research support from Kadmon Corporation\*, Palladio Biosciences\*, Reata Pharmaceuticals\*, and Sanofi-Genzyme\*; serving as a steering committee member for Palladio Biosciences\* and Sanofi-Genzyme\*; and receiving fees from UpToDate. GKR reports receiving research support from Danone Research\*, National Health and Medical Research Council of Australia\*, Otsuka Australia\*, and PKD Australia\*; speaker honoraria from Otsuka Australia Pharmaceutical\*; serving on the advisory board for Sanofi; serving on a scientific advisory board for PKD Australia; and receiving travel expenses from Asia Pacific Society of Nephrology. BR reports serving on an advisory board for AstraZeneca, Bayer, Sanofi-Genzyme, and Servier; and receiving speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Cipla, Novartis, Sanofi-Genzyme, and Servier. RT reports receiving consultancy fees from Otsuka Pharmaceutical; speaker honoraria from Otsuka Pharmaceutical; travel expenses from Otsuka Pharmaceutical; serving on an advisory board for the Independent Data Monitoring Committee, TEMPO trial; and serving as current President of the European Renal Association. CEG reports receiving consultancy fees from Alexion and Calliditas; research support from Alexion; and speaker honoraria from Alexion. RAM reports receiving consultancy fees from the World Health Organization and the Evidence Foundation; research support from the American College of Radiology, the

American Society of Hematology, Boehringer Ingelheim, and the NIDDK; speaker honoraria from Evidence Foundation and Institute for Clinical and Economic Review (ICER); and participating in an advisory board for National Institutes of Health, the board of directors for Evidence Foundation, and the medical advisory board for National Kidney Foundation. OD reports receiving consultancy fees from Otsuka Pharmaceutical\*, Sanofi-Genzyme\*, and Vertex Pharmaceuticals\*; and serving on advisory boards for Galapagos\* and Otsuka Pharmaceutical.\* All the other authors declared no competing interests.

\*Monies paid to institution.

## ACKNOWLEDGMENTS

We dedicate this clinical practice guideline to the memory of our dear colleague and friend, Tess Harris. Her tireless advocacy, positive spirit, and unwavering kindness inspired all who knew her. This guideline would not have been possible without her significant contributions.

A special debt of gratitude is owed to the following people for their contribution to this important guideline effort: Michael Cheung, Melissa Thompson, Debbie Maizels, Jennifer M. King, Gaelen P. Adam, Ian J. Saldanha, Michael Zahradnik, Wangnan Cao, Lucille Xiang, Morgan E. Grams, and Michel Jadoul. We also are thankful for all the people who provided helpful comments and suggestions during the public review of the guideline.

## ADDITIONAL INFORMATION

Only key references, including major reviews, guidelines, and those supporting the figures, have been included. Please refer to the full guideline for detailed references.

Supplementary material is available online at [www.kidney-international.org](http://www.kidney-international.org).

## REFERENCES

- Chapman AB, Devuyst O, Eckardt K-U, et al.; Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int.* 2015;88:17–27.
- Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). *Kidney Int.* 2025;107:S1–S239.
- Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. *Nat Rev Dis Primers.* 2018;4:50.
- Corne-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. *Lancet.* 2019;393:919–935.
- Olaizola P, Rodrigues PM, Caballero-Camino FJ, et al. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. *Nat Rev Gastroenterol Hepatol.* 2022;19:585–604.
- Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int.* 2015;88:17–27.
- Devuyst O, Knoers NV, Remuzzi G, et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. *Lancet.* 2014;383:1844–1859.
- Devuyst O, Olinger E, Weber S, et al. Autosomal dominant tubulointerstitial kidney disease. *Nat Rev Dis Primers.* 2019;5:60.
- Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. *J Am Soc Nephrol.* 2015;26:160–172.
- Lavu S, Vaughan LE, Senum SR, et al. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. *JCI Insight.* 2020;5:e138724.
- Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int.* 2021;99:S1–S87.
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. *Arthritis Care Res (Hoboken).* 2020;72:744–760.
- Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. *J Urol.* 2019;202:282–289.
- Lantinga MA, Casteleijn NF, Geudens A, et al. Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review. *Nephrol Dial Transplant.* 2017;32:144–150.
- Lantinga MA, Darding AJ, de Sevaux RG, et al. International multi-specialty Delphi survey: identification of diagnostic criteria for hepatic and renal cyst infection. *Nephron.* 2016;134:205–214.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney Int Suppl.* (2011). 2017;7:1–59.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int.* 2024;105: S117–S314.
- Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney Int Suppl.* 2012;2:279–335.
- Kidney Disease: Improving Global Outcomes (KDIGO) Lipids Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. *Kidney Int Suppl.* 2013;3:259–305.
- Chan CT, Blankestijn PJ, Dember LM, et al. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int.* 2019;96:37–47.
- Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. *J Am Soc Nephrol.* 2018;29:2458–2470.
- Muller RU, Messchendorp AL, Birn H, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. *Nephrol Dial Transplant.* 2022;37:825–839.
- Bugazia S, Hogan MC. Extrarenal manifestations: polycystic liver disease and its complications. *Adv Kidney Dis Health.* 2023;30:440–453.
- Perrone RD, Malek AM, Watnick T. Vascular complications in autosomal dominant polycystic kidney disease. *Nat Rev Nephrol.* 2015;11:589–598.
- Chebib FT, Nowak KL, Chonchol MB, et al. Polycystic kidney disease diet: what is known and what is safe. *Clin J Am Soc Nephrol.* 2023;19:664–682.
- Burgner A, Hladunewich MA. Contraception and CKD. *Clin J Am Soc Nephrol.* 2020;15:563–565.
- Wiles K, Chappell L, Clark K, et al. Clinical practice guideline on pregnancy and renal disease. *BMC Nephrol.* 2019;20:401.
- Wiles K, Chappell LC, Lightstone L, et al. Updates in diagnosis and management of preeclampsia in women with CKD. *Clin J Am Soc Nephrol.* 2020;15:1371–1380.
- Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics.* 2017;140:e20171904.
- Gimpel C, Bergmann C, Bockenbauer D, et al. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. *Nat Rev Nephrol.* 2019;15:713–726.
- EAF Co-Chairs, Harris T, Sandford R, et al. European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants. *Nephrol Dial Transplant.* 2018;33:563–573.
- Mao Z, Chong J, Ong AC. Autosomal dominant polycystic kidney disease: recent advances in clinical management. *F1000Res.* 2016;5:2029.
- Ong AC, Devuyst O, Knebelmann B, et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. *Lancet.* 2015;385:1993–2002.